Cerecor Inc. (CERC) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS
Cerecor Inc. (NASDAQ:CERC) posted its earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.15, MarketWatch Earnings reports. Cerecor had a negative net margin of 864.87% and a negative return on equity of 896.66%. The firm had revenue of $0.16 million during the quarter.
Shares of Cerecor (NASDAQ CERC) opened at 0.5852 on Tuesday. The company’s market cap is $8.24 million. The stock has a 50 day moving average of $0.72 and a 200 day moving average of $0.68. Cerecor has a 1-year low of $0.34 and a 1-year high of $5.60.
In related news, Director Armistice Capital Master Fund purchased 72,672 shares of the stock in a transaction dated Friday, May 19th. The stock was purchased at an average price of $0.63 per share, with a total value of $45,783.36. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.70% of the stock is owned by insiders.
Cerecor Company Profile
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.